“Innovations DivisionThe Innovation Division continues to be...

“Innovations DivisionThe Innovation Division continues to be primarily focused on its flagship project, being the commercialisation of the Sr-HT-Gahnite Cervical Spinal Cage. This project continues to see positive results. Allegra remains on track to submit this project for regulatory 510k approval with the US Federal Drug Administration (FDA) on or around 31st March 2023.”